.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Argus Health
Farmers Insurance
Deloitte
Merck
Medtronic
Boehringer Ingelheim
Chubb
McKesson

Generated: November 19, 2017

DrugPatentWatch Database Preview

NATEGLINIDE Drug Profile

« Back to Dashboard

Which patents cover Nateglinide, and when can generic versions of Nateglinide launch?

Nateglinide is a drug marketed by Zydus Pharms Usa Inc, Alvogen Malta, Dr Reddys Labs Ltd, Watson Labs, Par Pharm, and Teva Pharms. and is included in six NDAs.

The generic ingredient in NATEGLINIDE is nateglinide. There are nine drug master file entries for this compound. Twelve suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the nateglinide profile page.

Pharmacology for NATEGLINIDE

Drug ClassGlinide
Mechanism of ActionPotassium Channel Antagonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms Usa Inc
NATEGLINIDE
nateglinide
TABLET;ORAL205248-001Jul 6, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Watson Labs
NATEGLINIDE
nateglinide
TABLET;ORAL077462-001Mar 30, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Alvogen Malta
NATEGLINIDE
nateglinide
TABLET;ORAL205055-002Dec 11, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
NATEGLINIDE
nateglinide
TABLET;ORAL077467-002Sep 9, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson Labs
NATEGLINIDE
nateglinide
TABLET;ORAL077462-002Mar 30, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa Inc
NATEGLINIDE
nateglinide
TABLET;ORAL205248-002Jul 6, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Alvogen Malta
NATEGLINIDE
nateglinide
TABLET;ORAL205055-001Dec 11, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
NATEGLINIDE
nateglinide
TABLET;ORAL077461-002Sep 9, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
NATEGLINIDE
nateglinide
TABLET;ORAL077461-001Sep 9, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
NATEGLINIDE
nateglinide
TABLET;ORAL077463-002Sep 9, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Argus Health
Boehringer Ingelheim
UBS
McKinsey
Mallinckrodt
Federal Trade Commission
Cerilliant
Deloitte
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot